期刊文献+

影响伦理审查速度的因素分析 被引量:6

Analysis of Factors Affecting the Speed of Ethic Review
下载PDF
导出
摘要 目的 通过分析药物临床试验项目伦理审查各环节的耗时情况,探讨提高审查效率的可能途径。方法以在我院药物临床试验伦理委员会审查并拿到批件的99个药物临床试验项目为研究对象,针对会议审查和快速审查项目,分别采集审查各个环节所需时间进行分析。结果 会议审查及快速审查项目的平均审查时间分别为43.7和40天,在一个月内完成审查的项目占40%,绝大多数项目在2个月内完成伦理审查;在伦理审查的各个环节中,从上会到拿到批件耗时最长,约占审查总时长的53.6%。预审环节平均消耗时间为2.1~2.3天;伦理审查过程中,申办方及研究者所用的时间明显多于伦理委员会消耗的时间,在会议审查及快速审查中,申办方及研究者与伦理委员会的耗时比分别为1.69及3.8。结论 在伦理审查的过程中,申办方、研究者及伦理委员会须各尽其责、加强沟通,以提高伦理审查效率。 Objective:To explore the possible methods to improve the efficiency of ethical review by analysis of the time consumptions about the drug clinical trials program in different sections of ethical review. Methods : Time consumption data in the review procession were collected from 99 trials that were approved by the Clinical Trial Ethical Review Committee of Peking Union Medical College Hospital (PUMCH). The review included both convened meeting and expedited review. Results: The average time of review for convened meeting and expedited review were 43.7 and 40 days, respectively. 40% of the reviews completed in 1 month, most reviews were done in 2 months. Among all the sections of review, the longest part which took 53.6% of the whole review time was from convened meeting until getting the approval. The average review time for the pre - reviews was 2.1 to 2.3 days. During the ethical review, sponsors and investigators consumed much longer time than ethics committee. For convened meeting and expedited review, the time consumed by sponsors was 1.69 and 3.8 times to the time consumed by ethic committee, respectively. Gonclusion: During the ethical review, each one of sponsor, investigator and ethical committee should take its responsibility to enhance the communication and improve the efficiency of ethical review.
出处 《中国医学伦理学》 2016年第3期465-468,共4页 Chinese Medical Ethics
关键词 伦理审查 临床试验 创新药研发 伦理委员会 Ethical Review Clinical Trials Researchand Development of Innovative Drugs Ethics Committee
  • 相关文献

参考文献10

  • 1高军,许方霄.国内药品审评速度亟待加快 全国人大代表杜振新谈药品审评机制改革[J].首都医药,2014(7):31-31. 被引量:1
  • 2国家食品药品监督管理总局.关于药品注册审评审批若干政策的公告(2015年第230号)[A/OL].(2015-11-11)[2016-02-16].http://www.sfda.gov.cn.
  • 3梁伟雄.药物临床试验中不同伦理审查模式的比较[J].中国医学伦理学,2014,27(3):330-332. 被引量:8
  • 4Silberman G , Kahn KL. Burdens on Research Im- posed by Institutional Review Boards: The State of the Evidence and Its Implications for Regulatory Reform [J]. Milbank Q, 2011, 89 (4): 599 - 627.
  • 5Grady C. Do IRBs protect human research partici- pants[J]. JAMA,2010, 304(10) : 1122 - 1123.
  • 6Mascette AM, Bernard GR, Dimichele D, et al. Are Central Institutional Review Boards the Solution The National Heart, Lung, and Blood Institute Working Group "s Report on Optimizing the IRB Process[J]. Acad Med, 2012, 87(12): 1710 -1714.
  • 7Govindarajan, R., J.W. Young, C.L. Harless, et al. Barriers to Clinical Trials Vary According to the Type of Trial and the Institution [ J ]. Journal of Clinical Oncology , 2007, 25(12) : 1633 - 1634.
  • 8Whitney, S. N, Alcser, K, Schneider, C. E, et al. Principal investigator views of the IRB system [ J ]. International Journal of Medical Sciences, 2008, 5 (2) : 68 - 72.
  • 9李博,于晓松.医院药物临床试验伦理审查程序的研究与探索[c]//沈阳:中华医学会医学伦理学分会第十六届年会论文汇编,2011:72-75.
  • 10蔡昱,张金钟,陆于宏,钟鸣.天津市伦理委员会现状调查分析[J].医学与哲学(A),2013,34(5):29-32. 被引量:4

二级参考文献10

共引文献10

同被引文献55

引证文献6

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部